Boron neutron capture reaction mediator (null)

The term "boron neutron capture reaction mediator" does not refer to a specific molecule or receptor but rather describes any chemical agent capable of delivering the stable isotope **boron‑10 (^10B)** into target cells—primarily cancer cells—for use in **boron neutron capture therapy (BNCT)**. These mediators are typically small molecules such as *boronophenylalanine* (**BPA**) or *sodium borocaptate* (**BSH**) that exploit metabolic differences between cancerous and normal tissues—such as overexpression of certain amino acid transporters—to achieve preferential accumulation within tumors. After administration and sufficient uptake by malignant tissue, patients are exposed to low-energy neutrons; when these interact with ^10B atoms inside the cell, they trigger a nuclear reaction that emits high-energy alpha particles and lithium ions. These products have extremely short ranges (~5–9 μm) so their cytotoxic effects are highly localized—destroying only those cells containing significant amounts of ^10B while sparing adjacent healthy tissue. This approach is considered an advanced form of targeted radiotherapy with potential applications across several difficult-to-treat cancers. However, "mediator" is not itself a therapeutic target but rather denotes an entire class or functionally defined group (*i.e.*, any molecule capable of mediating this reaction). Therefore: - It is **not considered a therapeutic target like receptors/enzymes**, but instead refers collectively to agents used for BNCT. - The entry appears incorrect if interpreted as referring to an individual protein/gene/receptor. In summary: "Boron neutron capture reaction mediator" should be understood as referring generically to any agent that delivers boron‑10 into biological targets for BNCT—not as a discrete molecular entity suitable for structured drug-target databases.

Other names

Boron delivery agentBoron carrierBNCT boron compoundBoron-10 compoundBPA (boronophenylalanine)BSH (sodium borocaptate)

Compounds containing the stable isotope **boron‑10 (^10B)** are selectively taken up by tumor cells. Upon exposure to low-energy neutrons during therapy (**BNCT**, Boron Neutron Capture Therapy), ^10B captures neutrons and undergoes nuclear fission. - This produces high-energy alpha particles and lithium nuclei with very short pathlengths (~one cell diameter). - The resulting localized radiation destroys the tumor cell from within while sparing surrounding healthy tissue